Apellis Pharmaceuticals Inc.
Apellis Pharma focuses on complement‑targeted therapies, with FDA‑approved EMPAVELI (PNH) and SYFOVRE (GA). Ongoing late‑stage trials for C3 glomerulopathy and siRNA APL‑3007, plus partnerships with Biovitrum and Beam Therapeutics, drive growth in high‑need niche markets.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 705
- HQ: Waltham
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.